Back to all news

Deep Learning PET Biomarkers Outperform Clinical Tools in Prostate Cancer Survival Prediction

AuntMinnieIndustry

Deep learning-derived PET biomarkers more accurately predict metastatic prostate cancer survival than standard clinical risk models.

Key Details

  • 1Study involved 486 PSMA PET scans from metastatic prostate cancer patients (2017-2025).
  • 2A deep learning (DL) model and a multimodal fusion model (imaging plus clinical data) were evaluated.
  • 3Compared against established risk tools: VISION nomogram, Templeton score, NLR, SUVmax, CHAARTED, LATITUDE classifications.
  • 4The fusion model achieved highest predictive accuracy: time-dependent AUC of 0.86.
  • 5Median overall survival in patient cohort was 2.1 years.

Why It Matters

These findings support the potential of AI-driven PET biomarkers to improve survival prediction for metastatic prostate cancer, potentially enabling better treatment decision-making and patient stratification.

Ready to Sharpen Your Edge?

Subscribe to join 11k+ peers who rely on RadAISlice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.